Navigation Links
Strong immune response to new siRNA drugs in development may cause toxic side effects
Date:5/20/2009

New Rochelle, NY, May 20, 2009Small synthetic fragments of genetic material called small interfering RNA (siRNA) can block production of abnormal proteins; however, these exciting new drug candidates can also induce a strong immune response, causing toxic side effects. Understanding how siRNA stimulates this undesirable immune activity, how to test for it, and how to design siRNA drugs to avoid it are critical topics explored in a timely review article published online ahead of print in Oligonucleotides, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com) The article is available free online at www.liebertpub.com/oli

siRNAs are duplex structures comprised of short oligonucleotide sequences. The discovery that naturally occurring and synthetic siRNAs can effectively prevent expression of a disease gene sparked intense interest in developing siRNAs as drugs. However, depending on the structure and sequence of a siRNA and how it is delivered, it may induce a potent innate immune response in humans, stimulating the release of inflammatory chemicals such as cytokines and interferons.

Exploring the possibility of designing synthetic siRNAs and developing novel delivery methods that would exploit the drug-like capabilities of siRNA while preventing toxic side effects, researchers are working to understand the mechanism by which siRNA stimulates the immune system. In the article entitled, "siRNA and Innate Immunity," Marjorie Robbins, Adam Judge, and Ian MacLachlan, from Tekmira Pharmaceuticals (Burnaby, British Columbia, Canada), describe the different possible mechanisms for siRNA-mediated immune activation in various cell types, present preferable siRNA sequences and strategies for chemically modifying the siRNA to minimize its immunostimulatory effects, and suggest experimental methods for studying the safety of siRNA therapeutics.

The authors conclude, "We are confident that through the judicious application of well-informed siRNA design and the use of increasingly effective delivery systems, demonstrations of systemic siRNA in human subjects will soon be realized."

"This is perhaps the most comprehensive review on siRNAs and innate immunity to date and a must read for anyone using siRNAs therapeutically," says John Rossi, PhD, Co-Editor-in-Chief of Oligonucleotides and Professor in the Department of Molecular Biology, Beckman Research Institute of the City of Hope (Duarte, CA).


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. Analysis finds strong match between molecular, fossil data in evolutionary studies
2. As good as it gets: Octogenarian muscles dont get stronger with exercise
3. Information warfare in the 21st century: Ideas are sometimes stronger than bombs
4. AJCN study shows moderate alcohol consumption related to stronger bones
5. Building strong bones: Running may provide more benefits than resistance training, MU study finds
6. Research uncovers surprising lion stronghold in war-torn central Africa
7. Stronger coastal winds due to climate change may have far-reaching effects
8. Immunity stronger at night than during day
9. New type of vaccines deliver stronger and faster immune response
10. As sticky as a gecko... but 10 times stronger!
11. In a last stronghold for endangered chimpanzees, survey finds drastic decline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016   Veridium , a leader ... of new CEO James Stickland . Stickland, ... of experience, has served in senior executive roles ... specialized in expanding a pipeline of venture capital ... most recently served as managing director of U.K.-based ...
(Date:12/6/2016)... 2016 Valencell , the leading innovator ... seen a third consecutive year of triple digit growth ... 2016 with a 360 percent increase in companies who ... was driven by sales of its wrist and ear ... its technology for hearables for fitness and healthcare applications. ...
(Date:12/5/2016)... 2016  The Office of Justice Programs, National ... Scans Enhance or Replace Medico Legal Autopsies?" on ... or replacing forensic autopsies with postmortem X-ray computed ... In response to recommendations made by The National ... scans as a potential component of medicolegal death ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Maryland (PRWEB) , ... December ... ... announces the commercial launch of flexible packaging for their exceptionally efficient ... disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered to ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. ... and expansion clinical trial for its lead drug candidate, AC0010, at the World ... trial was to determine the safety, antitumor activity, and recommended phase II dosage ...
(Date:12/7/2016)... Corp. ("Zenith" or the "Company") announces webcast details for a ... and Special Meeting. The Zenith Annual and ... 15, 2016 at Mount Royal University, ... Gate SW, Calgary, Alberta , commencing at ... circular, containing the matters to be considered at the meeting, ...
Breaking Biology Technology: